Evidence map›Paper›PMID 29350080›Full record

ArticleLeukemia & lymphoma2018

IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.

Samir Mazharuddin, Anuja Chattopadhyay, Moshe Y Levy, Robert L Redner

Abstract readCase ReportsLetter
In one paragraph

Article in Leukemia & lymphoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Function of PML-RARA in Acute Promyelocytic Leukemia.Advances in experimental medicine and biology · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Pharmaceuticals (Basel, Switzerland) · 2021
    Article
  9. Review
  10. Review
  11. PLZF-RARCancers · 2020
    Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samir Mazharuddina Baylor University Medical Center , Dallas , TX , USA.
Anuja Chattopadhyayb UPMC Hillman Cancer Center and University of Pittsburgh , Pittsburgh , PA , USA.
Moshe Y Levya Baylor University Medical Center , Dallas , TX , USA.
Robert L Rednerb UPMC Hillman Cancer Center and University of Pittsburgh , Pittsburgh , PA , USA.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Translocation, GeneticAdultAntineoplastic AgentsBase SequenceCarrier ProteinsCell DifferentiationChromosomes, Human, Pair 1Chromosomes, Human, Pair 17DNA-Binding ProteinsHumansLeukemia, Promyelocytic, AcuteMaleNeoplastic Stem CellsNuclear ProteinsOncogene Proteins, FusionRetinoic Acid Receptor alphaAntineoplastic AgentsCarrier ProteinsDNA-Binding ProteinsIRF2BP2 protein, humanNuclear ProteinsOncogene Proteins, FusionRARA protein, humanRetinoic Acid Receptor alphaTranscription FactorsTretinoin

Identifiers

PMID29350080
PMCPMC6162987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.